The CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple MyEloma (ASPIRE) trial enrolled 780 patients at approximately 200 sites.
The primary endpoint of the trial is progression-free survival, while the secondary endpoints include overall survival, overall response rate, duration of response, disease control rate, safety, time-to-progression and time-to-next treatment.
Onyx Pharmaceuticals executive vice president Ted Love said the ASPIRE trial will support full approval of Carfilzomib for use in patients with relapsed multiple myeloma.
"We are pleased to have completed enrollment in the ASPIRE study ahead of schedule, and could have interim results as early as the first half of 2013," Love added.